Media stories about AveXis (NASDAQ:AVXS) have trended somewhat positive on Sunday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AveXis earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.3484770165562 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s analysis:

A number of brokerages recently issued reports on AVXS. Chardan Capital set a $103.00 price target on AveXis and gave the company a “buy” rating in a report on Sunday, June 18th. Sanford C. Bernstein began coverage on AveXis in a report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price target for the company. Morgan Stanley began coverage on AveXis in a report on Thursday. They issued an “overweight” rating and a $118.00 price target for the company. Zacks Investment Research upgraded AveXis from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, Citigroup Inc. set a $100.00 price target on AveXis and gave the company a “buy” rating in a report on Thursday, June 15th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. AveXis has an average rating of “Buy” and an average price target of $93.60.

AveXis (NASDAQ AVXS) traded up 1.62% during mid-day trading on Friday, reaching $96.35. The company’s stock had a trading volume of 297,905 shares. The firm’s market capitalization is $2.68 billion. AveXis has a 52 week low of $31.55 and a 52 week high of $97.00. The company’s 50-day moving average price is $80.67 and its 200 day moving average price is $71.89.

AveXis (NASDAQ:AVXS) last posted its earnings results on Thursday, May 11th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.13. During the same quarter in the previous year, the business posted ($1.24) EPS. On average, equities analysts forecast that AveXis will post ($4.27) earnings per share for the current fiscal year.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $70.91, for a total value of $126,219.80. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $126,219.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 5,340 shares of company stock valued at $434,872 in the last three months. 18.60% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “AveXis (AVXS) Getting Somewhat Positive Press Coverage, Study Shows” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with's FREE daily email newsletter.